AI Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin condition marked by red-orange patches and thickened skin, posing challenges in treatment.
- Recent advancements in targeted biologic therapies, particularly ixekizumab, an interleukin-17 inhibitor, have shown promise in managing PRP with minimal side effects.
- A patient treated with ixekizumab experienced complications including Kaposi's varicelliform eruption and a pseudomonal superinfection three months post-treatment.
Article Abstract
Pityriasis rubra pilaris (PRP) is a rare condition characterized by red-orange plaques with islands of sparing with follicular and palmoplantar hyperkeratosis. The disease can be difficult to treat and often requires patients to trial multiple therapeutic options. In recent years, targeted biologic therapies have increasingly been trialed due to their relative efficacy and favorable safety profile. Ixekizumab, an interleukin-17 inhibitor, is one such therapy that has demonstrated efficacy in PRP with few reported adverse events. We present a PRP patient who developed Kaposi's varicelliform eruption followed by a pseudomonal superinfection three months after initiation of ixekizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231903 | PMC |
| http://dx.doi.org/10.7759/cureus.38395 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!